Home > Expanded Access > Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

Merck Sharp & Dohme Corp.

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

Official Title: 
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options
Brief Summary: 
This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is patient driven. Investigators are not proactively assigned. There is no target sample size and duration of the study is indefinite. For information on how to enroll in the study, see link below.
Approved for marketing
HIV Infections

Drug: raltegravir
raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
Other Name: MK0518
Other Name: ISENTRESS™

Eligibility Criteria: 

Inclusion Criteria:

- HIV positive patients who have limited or no treatment options and have documented resistance

Exclusion Criteria:

- Patient has previously been on MK0518 therapy

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 16 Years

Medical Monitor
Study Director
Merck Sharp & Dohme Corp.

Merck Sharp & Dohme Corp.
EA Number: 
MeSH Terms: 
HIV Infections, Anti-Retroviral Agents, Raltegravir Potassium
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.